U.S. regulator rejects Novartis heart failure drug

May 16, 2014 12:35 PM

6 0

U.S. regulator rejects Novartis heart failure drug

ZURICH (Reuters) - U.S. health regulators turned down an application to approve Novartis' experimental heart failure drug due to insufficient evidence that it improves symptoms, the Swiss drugmaker said on Friday.

Novartis said in a statement the Food and Drug Administration (FDA) had asked for further evidence to determine the efficacy of serelaxin, also known as RLX030.

Read more

To category page

Loading...